In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Although polycythemia vera management remains focused on reducing the risk of thrombotic events, there is growing recognition ...

Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood ...

A consistently high haemoglobin level, medically known as polycythemia, can lead to serious health issues if not managed.

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

Protagonist Therapeutics (PTGX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

"Protagonist is approaching multiple transformational events with the pending readouts of JNJ-2113 in Phase 3 psoriasis studies this year, Phase 2b ulcerative colitis study in Q1 2025, and rusfertide ...

and a multiple dose study in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD), and a Phase 2 study of DISC-3405 in polycythemia vera (PV). “With this non-dilutive $200 million ...

The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and ...